KEGG   DRUG: Spartalizumab
Entry
D11605                      Drug                                   
Name
Spartalizumab (USAN/INN);
Spartalizumab (genetical recombination) (JAN)
Sequence
(Heavy chain)
EVQLVQSGAE VKKPGESLRI SCKGSGYTFT TYWMHWVRQA TGQGLEWMGN IYPGTGGSNF
DEKFKNRVTI TADKSTSTAY MELSSLRSED TAVYYCTRWT TGTGAYWGQG TTVTVSSAST
KGPSVFPLAP CSRSTSESTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
SLSSVVTVPS SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP SQEEMTKNQV
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF
SCSVMHEALH NHYTQKSLSL SLG
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCKSSQSLL DSGNQKNFLT WYQQKPGQAP RLLIYWASTR
ESGVPSRFSG SGSGTDFTFT ISSLEAEDAA TYYCQNDYSY PYTFGQGTKV EIKRTVAAPS
VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS
LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
(Disulfide bridge: H22-H96, H131-L220, H144-H200, H223-H'223, H226-H'226, H258-H318, H364-H422, H'22-H'96, H'131-L'220, H'144-H'200, H'258-H'318, H'364-H'422, L23-L94, L140-L200, L'23-L'94, L'140-L'200)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
Comment
Monoclonal antibody
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D11605  Spartalizumab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D11605  Spartalizumab (USAN/INN)
Other DBs
CAS: 1935694-88-4
PubChem: 405226472
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system